立即登录 | 免费注册
全部学科 | 内科学 | 心血管病学 | 内分泌学与糖尿病 | 神经病学 | 消化病学 | 呼吸病学 | 肿瘤学 | 妇产科学 | 骨科学
疾病中心： 高血压 | 冠心病 | 心力衰竭 | 心律失常 | 脂肪性肝病 | 糖尿病 | 卒中 | 慢性阻塞性肺病 | 子宫内膜异位症 | 乳腺癌 | 肺癌 | 结直肠癌 | 器官移植
Loading
当前位置：期刊中心 > 全球精选文摘 > 文摘导读

黏液性细胞而非透明细胞的组织学与接受紫杉醇联合铂类药物化疗的晚期卵巢癌患者的生存率下降相关

Mucinous But Not Clear Cell Histology Is Associated With Inferior Survival in Patients With Advanced Stage Ovarian Carcinoma Treated With Platinum-Paclitaxel Chemotherapy
Bamias A, Psaltopoulou T, Sotiropoulou M   |    2010/7/30 15:42:55   | 
Cancer  |   2010   |          View at Publisher
专家评级： ★  |    循证评级： B   |  【全球专家评论】 |   打印| 推荐给好友
上一篇： 关于新的肺癌分期体系的详细信息及难点
下一篇： 改良Ivor-Lewis食管切除术后行辅助放疗：是否能预防胸中段食管癌的淋巴结复发？
Background:
Mucinous and clear cell histology have been associated with adverse prognosis in ovarian carcinomas. The authors compared the outcome of these subtypes with that of serous tumors in patients who were treated with combination paclitaxel/platinum at their center.

Methods:
Four hundred twenty patients with histologically confirmed, serous (n=367), mucinous (n=24), or clear cell (n=29) ovarian carcinomas, International Federation of Gynecology and Obstetrics stage III or IV disease, and who were treated with paclitaxel/platinum after cytoreductive surgery were included in this analysis.

Results:
The median overall survival for each histological subtype was 47.7 months (95% confidence interval [CI], 37.7-57.7 months) for serous, 15.4 months (95% CI, 4.2-26.6 months) for mucinous, and 36.6 months (95% CI, 22.7-50.5 months) for clear cell carcinomas. Cox regression analysis showed that mucinous histology was an independent predictor of poor prognosis compared with serous tumors (hazard ratio, 0.360; 95% CI, 0.215-0.603; P=.001). In contrast, such a difference between clear cell and serous carcinomas was not found (P=.337). Median survival of patients with mucinous tumors and residual disease >2cm was poor, averaging 7.1 months (95% CI, 4.6-9.6 months).

Conclusions:
Mucinous but not clear cell histology is associated with significantly worse prognosis in advanced ovarian cancer treated with combination platinum/paclitaxel. Different therapeutic strategies should be studied in this entity.
关键词:

请登录后发表评论，点击此处登录。

慢性心衰诊治：规范中求突破
黄峻
2012-2-1
南京医科大学第一附属医院
房颤治疗：手段渐趋丰富 新型治疗药物不断涌现 非药物治疗备受关注
马长生
2012-2-1
首都医科大学附属北京安贞医院
注重老年人群特征 优化管理

刘梅林
2012-2-1
北京大学第一医院老年内科

 
相关文章